

Arthritis Monoclonal Antibodies Market Grows At Rate 12% Due To Increasing Prevalence Of Arthritis

The Business Research Company's Arthritis Monoclonal Antibodies Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, April 28, 2022 /EINPresswire.com/ -- The increasing prevalence of arthritis globally has contributed to the [arthritis monoclonal antibodies market growth](#).


According to the Centre for Disease Control and Prevention (CDC), in 2020, the adult percentage of arthritis is 23% in USA which varies by country and

osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1% and the worldwide estimates of osteoarthritis include 9.6% men and 18% women. The increased prevalence of arthritis and the demand for personalized medicine is increasing the demand for the arthritis MAbs market.

The global [arthritis monoclonal antibodies market size](#) is expected to grow from \$44.14 billion in 2021 to \$49.44 billion in 2022 at a compound annual growth rate (CAGR) of 12.02%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The arthritis monoclonal antibodies market share is expected to reach \$66.45 billion in 2026 at a CAGR of 7.7%.

Read more on the Global Arthritis Monoclonal Antibodies Market Report <https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report>

The development of therapeutic monoclonal antibody products is becoming an indispensable



Arthritis Monoclonal Antibodies Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and has good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

Major players covered in the global arthritis monoclonal antibodies industry are Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, and Mylan N.V.

TBRC's global arthritis monoclonal antibodies market research report is segmented by drug into remicade, humira, enbrel, rituxan, orenzia, actemra, simponi, cimzia, remsima, by application into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, others, by end-user into hospitals, research institutes, others.

Arthritis Monoclonal Antibodies Global Market Report 2022 – By Drug (Remicade, Humira, Enbrel, Rituxan, Orenzia, Actemra, Simponi, Cimzia, Remsima), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia), By End-Use (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a arthritis monoclonal antibodies market overview, arthritis monoclonal antibodies market forecast arthritis monoclonal antibodies market size and growth for the whole market, arthritis monoclonal antibodies market segments, geographies, arthritis monoclonal antibodies market trends, arthritis monoclonal antibodies market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Arthritis Monoclonal Antibodies Market Report
<https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Conjugated Monoclonal Antibodies Global Market Report 2022 – By Drugs (Adcetris, Kadcyła), By Technology (Cleavable Linker, Non-cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodie-global-market-report>

Cancer Monoclonal Antibodies Global Market Report 2022 – By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbix), Panitumumab (Vectibix)), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer), By End User (Hospitals And Clinics, Research Laboratories, Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodie-global-market-report>

Monoclonal Antibodies (MAbs) Global Market Report 2022 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End-User (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fi0rV8cR5DxlCpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/570284277>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.